Poxel's share price climbed on Tuesday, following the publication in the Journal of Hepatology of positive results from its Phase II trial in NASH.

For the record, this clinical trial with PXL065 had met its primary efficacy endpoint of reducing fat mass in the liver after 36 weeks of treatment at all doses.

An improvement in fibrosis of at least one stage without worsening of NASH, one of the criteria for FDA approval, was observed in 31-50% of patients receiving PXL065 versus 17% in the placebo group.

Dr. Stephen Harrison, lead author of the article and principal investigator of the study, considers this publication in such a prestigious journal to be an "important milestone" in the development of new treatments for NASH.

With PXL065, a promising and differentiated clinical profile is emerging, combining a reduction in fat mass in the liver, improvements in fibrosis and metabolic benefits, with very good safety and security", emphasizes the doctor.

PXL065 deserves to be studied further in a pivotal study that could lead to a major new oral drug for the treatment of NASH, with the additional possibility of using it in combination with other therapies', he adds.

Following these announcements, Poxel shares climbed almost 33% on Tuesday on the Paris Bourse.

Copyright (c) 2023 CercleFinance.com. All rights reserved.